Table 3. Trials for Oligometastatic Disease.
Year | Author | Protocol | Patients | Site | No. oflesions | LC | DC | PFS | OS | Reference |
2007 | Milano | 50 Gy in 10 fx | 121 | Lung, Liver, Brain, Adrenal glands, Bone, Thoracic, pelvic, or abdominal lymph nodes | ≤5 | 2-year 67%;4-year 60% | 2-year 34%;4-year 34% | 2-year 26%;4-year 20% | 2-year 50%;4-year 28% | 4 |
2008 | Salama | 24–60 Gy in 3–8 fx | 29 | Lung, Liver, Lymph nodes, Bone, Adrenal, Soft tissue | ≤5 | Median follow-up of 14.4 mo,79% without progressionin treated site | Median follow-upof 14.4 mo, 45%without distantdiseaseprogression | 21% at median of14.4 months | NR | 7 |
2009 | Lee | Median dose 41.8 Gyin 6 fx | 68 | Liver | 1–8 | 1-year 71% | NR | NR | 17.6 monthsmediansurvival | 3 |
2009 | Rusthoven | Phase I 48–60 Gyin 3 fx; Phase II 60 Gyin 3 fx | 38 | Lung | 1–3 | 1-year 100%;2-year 96% | NR | Distal progressionin 64% of pts(median4 months) | 2-year 55% inpts w/o priorsystemic therapy;2-year 32% inpts with at leastone priorregimen | 5 |
2009 | Rusthoven | Phase I 36–60 Gyin 3 fx; Phase II 60 Gyin 3 fx | 47 | Liver | 1–3 | 1-year 95%;2-year 92% | NR | Distal progressionin 83% of pts(median of 6 months) | 2-year 30% | 6 |
2011 | Tong | Sunitinib 37.5 mg dailyfor 28 days; 50 Gyin 10 fx | 25 | Bone, Lung, Lymph nodes, Visceral | ≤5 | 18-month 75% | 18-month 52% | 18-month56% | 18-month 71% |
Abbreviations: LC, local control; DC, distant control; PFS, progression-free survival; OS, overall survival; fx, fractions; NR = not reported.